The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)
Open accessPublished version of a preprint
Abstract
Purpose: Multi-tyrosine kinase inhibitors (TKI) have shown clinical activity in patients with metastatic colorectal cancer. Cabozantinib, a multi-TKI, exhibited potent antitumor activity superior to regorafenib in preclinical colorectal cancer patient-derived tumor xenograft models. This phase II study aimed to investigate cabozantinib, a multi-TKI, in patients with refractory, metastatic colorectal cancer (mCRC). Experimental Design: A nonrandomized, two-stage, phase II clinical trial evaluating 12-week progression-free survival (PFS) was conducted in eight cancer centers across the United States between May 2018 and July 2020. Results: A total of 44 patients were enrolled between May 2018 and May 2019, 40 of which were response evaluable. Of the total 769 reported adverse events (AE), 93 (12%) were ≥ grade 3. Five grade 5 AEs were reported of which four were unrelated to study drug and one was reported as possibly related due to bowel perforation. Eighteen patients (45%) achieved 12-week PFS with stable disease or better (confidence interval, 0.29–0.62; P < 0.001). One patient (3%) had a partial response, and 27 other patients achieved stable disease as best response per RECISTv1.1. Median PFS was 3.0 months, and median overall survival was 8.3 months. Of the 18 patients who achieved 12-week PFS, 12 had left-sided primary tumors, 11 were RAS wild type, 11 were PIK3CA wild type, and 6 had previous regorafenib therapy. The 12-week PFS rate was higher in RAS wild-type tumors compared with RAS mutant tumors (0.61 vs. 0.32; P = 0.11). Conclusions: This phase II study demonstrated clinical activity of cabozantinib in heavily pretreated, patients with refractory mCRC, and supports further investigation. Significance: Targeting angiogenesis through VEGF axis blockade provides incremental survival benefit in patients with mCRC. The hepatocyte growth factor/MET signal transduction pathway has been observed as a mechanism for acquired resistance. Dual inhibition of VEGF plus MET is an attractive therapeutic strategy. This phase II trial demonstrated clinical activity with cabozantinib, a multi-TKI targeting VEGFR2 and MET, in patients with refractory, mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The combination of anti-MET therapy using a multi-tyrosine kinase inhibitor cabozantinib [51] or tepotinib [52] with anti-EGFR therapy may be effective in patients with acquired resistance to anti-EGFR therapy through MET amplification [53] (Figure 1).”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“While antiangiogenics have demonstrated incremental improvement in survival benefit, resistance to angiogenic inhibition uniformly develops over months in patients with mCRC (12, 13).”
BackgroundColorectal cancer statistics, 2020
Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21601 · Cited by 4,880
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“, PD-1, nivolumab, pembrolizumab; and CTLA-4, ipilimumab) have also been FDA approved for use as first-line agent for microsatellite instable (MSI) tumor types (4, 5).”
BackgroundGrothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“4 months over best supportive care and treatment resistance is inevitable (9, 10).”
BackgroundCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · cited 1×
“Recently, studies have also shown potential for targeted inhibitors eliciting clinical responses in KRASG12C-mutant colorectal cancer (7, 8).”
Background
Research works printed but not linked: 1
- Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 · DOI · Paper page
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“The combination of anti-MET therapy using a multi-tyrosine kinase inhibitor cabozantinib [51] or tepotinib [52] with anti-EGFR therapy may be effective in patients with acquired resistance to anti-EGFR therapy through MET amplification [53] (Figure 1).”
MethodCabozantinib for the treatment of solid tumors: a systematic review
Maroto, P., Porta, C., Capdevila, J., Apolo, A. B., Viteri, S., Rodríguez‐Antona, C., Martín, L., & Castellano, D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221107112 · Cited by 66
Saeed, A., Park, R., Pathak, H. B., Al-Bzour, A. N., Dai, J., Phadnis, M. A., Al-Rajabi, R. M. T., Kasi, A., Baranda, J. C., Sun, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45960-2 · Cited by 60
“In a phase II clinical trial, cabozantinib has demonstrated single-agent disease-stabilizing activity in patients with chemore-fractory pMMR/MSS metastatic CRC 13 .”
Saeed, A., Park, R., Dai, J., Al-Rajabi, R. M. T., Kasi, A., Baranda, J. C., Williamson, S. K., Saeed, A., Ripp, J., Collins, Z. S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100916 · Cited by 38
Evolving roles of MET as a therapeutic target in NSCLC and beyond
Lee, J. B., Shim, J. S. G., & Cho, B. C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01051-9 · Cited by 43
“However, cabozantinib, a type II TKI targeting MET as well as several other RTKs, as monotherapy 122 or in combination with durvalumab 116 was associated with ORRs of only 3–8% and median PFS durations of 3.0–3.7 months in patients with prior treatment with anti-EGFR antibody.”
Influential
Metadata
- Authors
- Scott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., & Messersmith, W. A.
- Affiliations
- University of Arizona Cancer Center (US)
- 2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
- Fox Chase Cancer Center (US)
- Thomas Jefferson University Hospital (US)
- 5Swedish Cancer Institute, Seattle, Washington.
- 6Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
- City Of Hope National Medical Center (US)
- Colorado School of Public Health (US)
- University of Colorado Cancer Center (US)
- Corresponding author
- Scott, Aaron J.
- ORCID
- Venue
- Cancer Research Communications
- Published
- 2022-10-14
- Volume
- 2
- Issue
- 10
- Pages
- 1188-1196
- ISSN
- 2767-9764 (ISSN-L)
- PMC
- PMC10035393
- OpenAlex
- W4295865084
- Cited by
- 18
- References
- 58
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 1 · 2022: 2
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancer Research Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Exelixis
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cabozantinib, metastatic colorectal cancer, refractory disease, tyrosine kinase inhibitors, RAS mutations, PIK3CA mutation, progression-free survival, regorafenib, acquired resistance, adverse events, intestinal perforation
- MeSH terms
- Anilides, Humans, Phenylurea Compounds, Prospective Studies, Pyridines, Colorectal Neoplasms, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). https://app.cochat.ai/papers/10.1158/2767-9764.crc-22-0169
- The paper
- Scott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., & Messersmith, W. A. (2022). A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-22-0169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.